Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Development Needs “Extreme Makeover,” Researcher Topol Says

Executive Summary

The pharmaceutical business needs an "extreme makeover," Cleveland Clinic cardiologist Eric Topol, MD, maintained during the 2004 Medical Innovation Summit in Cleveland

You may also be interested in...

Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test

The Vioxx withdrawal will prompt renewed debate over DTC advertising

COX-2 Class Is TARGET Of Critical Lancet Editorial

The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs

Rx Industry Pricing Model Must Change, Former Merck CEO Vagelos Says

The pharmaceutical industry needs to rethink its approach to pricing or face dire consequences, former Merck CEO Roy Vagelos told the Pharma, Biotech & Device Colloquium in Princeton, N.J. June 9

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts